Vir Biotechnology, Inc. VIR
We take great care to ensure that the data presented and summarized in this overview for Vir Biotechnology, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VIR
View all-
Sb Investment Advisers (Uk) LTD London, X016.7MShares$95.6 Million0.99% of portfolio
-
Black Rock Inc. New York, NY16.4MShares$94.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$73.4 Million0.0% of portfolio
-
State Street Corp Boston, MA5.73MShares$32.8 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.68MShares$15.4 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.3MShares$13.2 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA2.25MShares$12.9 Million0.45% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.62MShares$9.27 Million0.0% of portfolio
-
Bill & Melinda Gates Foundation Seattle, WA1.56MShares$8.93 Million26.84% of portfolio
-
Morgan Stanley New York, NY1.42MShares$8.16 Million0.0% of portfolio
Latest Institutional Activity in VIR
Top Purchases
Top Sells
About VIR
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Insider Transactions at VIR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 17
2025
|
Mark Eisner EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,586
-3.31%
|
$17,930
$5.47 P/Share
|
|
Jul 15
2025
|
Mark Eisner EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,796
-5.91%
|
$33,980
$5.47 P/Share
|
|
Jul 01
2025
|
Vicki L Sato Director |
SELL
Open market or private sale
|
Direct |
22,000
-1.67%
|
$110,000
$5.1 P/Share
|
|
Jun 09
2025
|
Robert J More Director |
BUY
Other acquisition or disposition
|
Indirect |
14,027
+2.68%
|
-
|
|
Jun 09
2025
|
Robert J More Director |
SELL
Other acquisition or disposition
|
Direct |
14,027
-25.65%
|
-
|
|
Jun 06
2025
|
Norbert W Bischofberger Director |
BUY
Other acquisition or disposition
|
Indirect |
10,667
+50.0%
|
-
|
|
Jun 06
2025
|
Norbert W Bischofberger Director |
SELL
Other acquisition or disposition
|
Direct |
10,667
-44.45%
|
-
|
|
Jun 02
2025
|
Janet Napolitano Director |
SELL
Open market or private sale
|
Direct |
3,200
-16.31%
|
$16,000
$5.05 P/Share
|
|
May 30
2025
|
Charles Elliott Sigal Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+20.1%
|
-
|
|
May 30
2025
|
Janet Napolitano Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+28.97%
|
-
|
|
May 30
2025
|
Saira Ramasastry Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+26.13%
|
-
|
|
May 30
2025
|
Vicki L Sato Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+0.6%
|
-
|
|
May 30
2025
|
Jeffrey S. Hatfield Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+20.1%
|
-
|
|
May 30
2025
|
Robert J More Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+12.76%
|
-
|
|
May 30
2025
|
Norbert W Bischofberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+25.0%
|
-
|
|
May 30
2025
|
Ramy Farid Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+25.0%
|
-
|
|
Apr 03
2025
|
Marianne De Backer Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
79,712
-9.39%
|
$398,560
$5.95 P/Share
|
|
Feb 26
2025
|
Vanina De Verneuil EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
7,373
-8.49%
|
$66,357
$9.14 P/Share
|
|
Feb 24
2025
|
George A Scangos Director |
SELL
Open market or private sale
|
Direct |
10,056
-1.42%
|
$90,504
$9.45 P/Share
|
|
Feb 24
2025
|
Ann M. Hanly EVP & Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
14,168
-10.73%
|
$127,512
$9.45 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 514K shares |
|---|---|
| Other acquisition or disposition | 1.22M shares |
| Open market or private sale | 214K shares |
|---|---|
| Other acquisition or disposition | 1.22M shares |